Vertex Suffers Setback In Its Search For Post-CF Blockbusters
Analysts Doubt Pipeline Potential
Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.
You may also be interested in...
After the failure of a second candidate for alpha-1 antitrypsin deficiency, Vertex may have to put its cash reserves to use in M&A.
Vertex and partner CRISPR Therapeutics hope CDX001 can offer a single-use curative regimen for sickle cell disease and beta thalassemia patients. A regulatory filing is possible within 18-24 months.
The biotech is growing fast thanks to its success in cystic fibrosis, but is under pressure to be bolder in its business development